Management of Type 1 Diabetes with Positive Autoantibodies

Risk Stratification and Management

The American Diabetes Association recommends that individuals with Type 1 diabetes autoantibodies be monitored closely and considered for teplizumab therapy to delay progression, with a 15% risk of developing clinical Type 1 diabetes within 10 years for those with a single autoantibody positive, and a 70% risk for those with two or more autoantibodies positive 1
The presence of multiple autoantibodies strongly indicates autoimmune etiology and predicts faster progression to insulin dependence, with a high risk of developing clinical Type 1 diabetes within 10 years 1

The Endocrine Society recommends consideration of teplizumab therapy to delay clinical onset in high-risk individuals identified through antibody testing, with longitudinal follow-up to track disease progression through stages with repeated metabolic assessments 1, 2
The American College of Endocrinology recommends initiation of insulin therapy immediately for individuals with overt hyperglycemia, with a starting dose of 0.3-0.4 units/kg/day total daily dose, and intensive glycemic control to reduce microvascular and macrovascular complications 3

The American Association of Clinical Endocrinologists recommends systematic screening for associated autoimmune conditions, including thyroid disease, celiac disease, and other autoimmune conditions, with testing for antithyroid peroxidase antibodies, TSH, and IgA tissue transglutaminase antibodies soon after diagnosis 4
The European Society for Paediatric Gastroenterology, Hepatology and Nutrition recommends measurement of IgA tissue transglutaminase antibodies soon after diabetes diagnosis, with documentation of normal total serum IgA levels, and repeat screening within 2 years of diabetes diagnosis, then again after 5 years 4

The International Society for Pediatric and Adolescent Diabetes recommends starting with GAD antibody testing in adults with phenotypic overlap between Type 1 and Type 2 diabetes, and completing an autoantibody panel that includes GADA, IA-2A, ZnT8A, and IAA 1, 2

The European Association for the Study of Diabetes recommends testing for islet autoantibodies, particularly GADA, in adults initially appearing to have Type 2 diabetes but with clinical clues suggestive of LADA, such as lower BMI, fewer metabolic risk factors, and personal or family history of autoimmune diseases 2
The American Diabetes Association recommends management of LADA following Type 1 diabetes principles once autoimmune etiology is confirmed, with progression to insulin dependence typically developing over years rather than weeks to months 2